Pulmonology Advisor22h
TNKase Approved for Treatment of Acute Ischemic Stroke
The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.
The Cardiology Advisor5d
ASA: Intra-Arterial Tenecteplase Beneficial for Large Vessel Occlusion
For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful thrombectomy results in improved likelihood of excellent outcome (modified ...
Renal & Urology News1d
FDA Approves TNKase for Acute Ischemic Stroke
(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Racine County Eye on MSN1d
Stroke survivor’s rapid recovery showcases life-saving emergency care by local medical personnel
Ascension Wisconsin recently honored Racine paramedics and the Ascension All Saints Hospital Emergency Department for their ...
EMS14d
FDA approves clot-dissolving agent for treatment of acute ischemic stroke
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
The Journal Times2d
Ascension recognizes medical staff, paramedics for quick response
Ascension All Saints Hospital recognized its medical staff and paramedics from the Racine Fire Department for their quick ...
pharmaphorum4d
Roche removes tenecteplase from phase 3 for stroke
Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator ...
Medscape6d
Critical Care
Recognized experts in acute pulmonary care discuss the benefits of pulmonary rehabilitation for patients recovering from CAP, including COVID pneumonia. Air Supply: Targeting Eosinophils in Severe ...